M
Matsontso Mathebula
Researcher at Sefako Makgatho Health Sciences University
Publications - 12
Citations - 653
Matsontso Mathebula is an academic researcher from Sefako Makgatho Health Sciences University. The author has contributed to research in topics: Vaccination & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 7, co-authored 10 publications receiving 503 citations. Previous affiliations of Matsontso Mathebula include University of South Africa & University of Limpopo.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Glenda E. Gray,Mary Allen,Zoe Moodie,Gavin J. Churchyard,Linda-Gail Bekker,Maphoshane Nchabeleng,Koleka Mlisana,Barbara Metch,Guy de Bruyn,Mary H. Latka,Surita Roux,Matsontso Mathebula,Nivashnee Naicker,Constance. Ducar,Donald K. Carter,Adrian Puren,Niles. Eaton,M. Juliana McElrath,Michael N. Robertson,Lawrence Corey,James G. Kublin +20 more
TL;DR: The MRKAd5 HIV- 1 vaccine did not prevent HIV-1 infection or lower viral-load setpoint; however, stopping the trial early probably compromised the ability to draw conclusions.
Journal ArticleDOI
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
Glenda E. Gray,Glenda E. Gray,Zoe Moodie,Barbara Metch,Peter B. Gilbert,Linda-Gail Bekker,Gavin J. Churchyard,Maphoshane Nchabeleng,Koleka Mlisana,Fatima Laher,Surita Roux,Kathryn Therese. Mngadi,Craig Innes,Matsontso Mathebula,Mary Allen,M. Julie McElrath,Michael N. Robertson,James G. Kublin,Lawrence Corey +18 more
TL;DR: The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism and is cautioned against further use of the Ad5 vector for HIV vaccines.
Journal ArticleDOI
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
Glenda Gray,Glenda Gray,Glenda Gray,Linda-Gail Bekker,Fatima Laher,Mookho Malahleha,Mary Allen,Zoe Moodie,Nicole Grunenberg,Yunda Huang,Doug Grove,Brittany Prigmore,Jia J. Kee,David Benkeser,John Hural,Craig Innes,Erica Lazarus,Graeme Meintjes,Nivashnee Naicker,Dishiki Jenny Kalonji,Maphoshane Nchabeleng,Modulakgotla Sebe,Nishanta Singh,Philip Kotze,Sheetal Kassim,Thozama Dubula,Vimla Naicker,William Brumskine,Cleon N. Ncayiya,Amy Ward,Nigel Garrett,Girisha Kistnasami,Zakir Gaffoor,Pearl Selepe,Philisiwe B. Makhoba,Matsontso Mathebula,Pamela Mda,Tania Adonis,Katlego S. Mapetla,Bontle Modibedi,Tricia Philip,Gladys Kobane,Carter Bentley,Shelly Ramirez,Simbarashe Takuva,Megan Jones,Mpho Sikhosana,Millicent Atujuna,Michele P. Andrasik,Nima S. Hejazi,Adrian Puren,Lubbe Wiesner,Sanjay Phogat,Sanjay Phogat,Carlos Diaz Granados,Marguerite Koutsoukos,Olivier Van Der Meeren,Susan W. Barnett,Niranjan Kanesa-thasan,James G. Kublin,M. Juliana McElrath,Peter B. Gilbert,Holly Janes,Lawrence Corey +63 more
TL;DR: In this article, a canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand.
Journal ArticleDOI
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
Zoe Moodie,Barbara Metch,Linda-Gail Bekker,Gavin J. Churchyard,Maphoshane Nchabeleng,Koleka Mlisana,Faatima. Laher,Surita Roux,Kathryn Therese. Mngadi,Craig Innes,Matsontso Mathebula,Mary Allen,Carter Bentley,Peter B. Gilbert,Michael N. Robertson,James G. Kublin,Lawrence Corey,Glenda Gray +17 more
TL;DR: The additional follow-up from HVTN 503-S supported the Phambili finding of increased HIV-1 acquisition among vaccinated men and strengthened the evidence of lack of vaccine effect among women.
Journal ArticleDOI
18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis
Ismaheel O. Lawal,Bernard Fourie,Matsontso Mathebula,Ingrid Moagi,Thabo Lengana,Nontando Moeketsi,Maphoshane Nchabeleng,Mark Hatherill,Mike Sathekge +8 more
TL;DR: A negative EOT 18F-FDG PET/CT result is protective against tuberculosis relapse, and nine percent of patients with RMA after ATT may experience tuberculosis relapse within 6 mo of completing ATT.